Skip to content

Study · Non-randomized trial · 2020

4 results

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

Davidson JA, Desouza C, Fonseca V, Frias JP, Van Gaal L, Giorgino F, Chao J, Dex TA, Roberts M, Saremi A, Leiter LA

Diabetic medicine : a journal of the British Diabetic Association26 Nov 2019Cited by 3 (Europe PMC)

PMID31365765 (opens in a new tab)PMCIDPMC7003844 (opens in a new tab)DOI10.1111/dme.14094 (opens in a new tab)PepBankPUB-31365765
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In participants with diabetes, iGlarLixi tended to produce weight loss or less weight gain than insulin glargine alone.

    In plain wordsIn participants with diabetes, added lixisenatide tended to reduce weight or weight gain versus insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Participants treated with iGlarLixi tended to show weight loss or less weight gain compared with participants receiving insulin glargine alone.
    1 context sentence
    Summary · context
    In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated
  2. 02HumanNon-randomized trialEfficacy outcome

    In participants with diabetes, average basal insulin dose at week 30 did not differ between iGlarLixi and insulin glargine arms.

    In plain wordsIn participants with diabetes, basal insulin dose was similar with added lixisenatide and insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    No significant changeDaily basal insulin dose at week 30
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No differences were observed in average daily basal insulin dose at week 30 between the two treatment arms or across the different FPG and PPG target groups.
    1 context sentence
    Summary · context
    In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated
  3. 03HumanNon-randomized trialSafety outcome

    In participants with type 2 diabetes, rates of any, documented symptomatic and clinically important hypoglycaemia were low across all groups, including lixisenatide alone.

    In plain wordsIn participants with diabetes, rates of low blood sugar events were low in all groups, including the lixisenatide-alone group.

    Peptide
    Lixisenatide
    Outcome
    Not applicableHypoglycaemia rates (any, documented symptomatic, clinically important) in the lixisenatide-alone arm
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hypoglycaemia rates [any, documented symptomatic (plasma glucose ≤ 3.9 mmol/l), and clinically important (plasma glucose < 3.0 mmol/l)] were low across all groups.
    2 context sentences
    Summary · context
    iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms
    Summary · context
    In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated
  4. 04HumanNon-randomized trialEfficacy outcome

    In participants with type 2 diabetes, iGlarLixi achieved more combined fasting and postprandial glucose targets than insulin glargine alone in both trials.

    In plain wordsIn participants with diabetes, more reached both glucose targets with added lixisenatide than with insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseCombined fasting and postprandial glucose target attainment
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Across treatment arms, iGlarLixi achieved the highest proportion of participants meeting both ADA- and AACE-recommended FPG and PPG targets at study end in both trials.
    2 context sentences
    Summary · context
    In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated
    Summary · context
    A higher proportion of participants in the iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA1c goals (P < 0.001 for overall comparisons), irrespective of ADA- or AACE-defined targets.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.